JP2018504412A - インフルエンザウイルスワクチン接種レジメン - Google Patents

インフルエンザウイルスワクチン接種レジメン Download PDF

Info

Publication number
JP2018504412A
JP2018504412A JP2017538596A JP2017538596A JP2018504412A JP 2018504412 A JP2018504412 A JP 2018504412A JP 2017538596 A JP2017538596 A JP 2017538596A JP 2017538596 A JP2017538596 A JP 2017538596A JP 2018504412 A JP2018504412 A JP 2018504412A
Authority
JP
Japan
Prior art keywords
influenza virus
domain
polypeptide
hemagglutinin
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017538596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504412A5 (enExample
Inventor
パレセ ピーター
パレセ ピーター
ガルシア‐サストレ アドルフォ
ガルシア‐サストレ アドルフォ
クラムメル フロリアン
クラムメル フロリアン
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2018504412A publication Critical patent/JP2018504412A/ja
Publication of JP2018504412A5 publication Critical patent/JP2018504412A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017538596A 2015-01-23 2016-01-22 インフルエンザウイルスワクチン接種レジメン Pending JP2018504412A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107166P 2015-01-23 2015-01-23
US62/107,166 2015-01-23
US201562215277P 2015-09-08 2015-09-08
US62/215,277 2015-09-08
PCT/US2016/014640 WO2016118937A1 (en) 2015-01-23 2016-01-22 Influenza virus vaccination regimens

Publications (2)

Publication Number Publication Date
JP2018504412A true JP2018504412A (ja) 2018-02-15
JP2018504412A5 JP2018504412A5 (enExample) 2019-03-07

Family

ID=56417854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538596A Pending JP2018504412A (ja) 2015-01-23 2016-01-22 インフルエンザウイルスワクチン接種レジメン

Country Status (6)

Country Link
US (1) US10736956B2 (enExample)
EP (1) EP3247389A4 (enExample)
JP (1) JP2018504412A (enExample)
AU (1) AU2016209032A1 (enExample)
CA (1) CA2974699A1 (enExample)
WO (1) WO2016118937A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3939604A3 (en) * 2016-10-21 2022-06-22 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
EP3606555A4 (en) * 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
EP3731862A1 (en) * 2017-12-29 2020-11-04 Development Center for Biotechnology A universal vaccine against influenza
WO2019169231A1 (en) 2018-03-02 2019-09-06 The University Of Chicago Methods and composition for neutralization of influenza
EP3810634A4 (en) * 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US12419946B2 (en) 2019-02-07 2025-09-23 Duke University Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
EP3927372A4 (en) * 2019-02-21 2023-01-25 Centivax, Inc. Optimized vaccine compositions and methods for making the same
EP3976095A1 (en) * 2019-06-02 2022-04-06 Pentavalent Bio Sciences PVT Ltd. Live attenuated universal influenza virus vaccines, methods and uses thereof
WO2021081120A1 (en) * 2019-10-22 2021-04-29 Icahn School Of Medicine At Mount Sinai Recombinant neuraminidase and uses thereof
WO2022087127A1 (en) * 2020-10-20 2022-04-28 Duke University Replication incompetent influenza vaccine platform for foreign protein delivery
AU2022223330A1 (en) * 2021-02-18 2023-08-24 Universität Basel Viral delivery of a sialidase to treat cancer
WO2023154821A2 (en) * 2022-02-11 2023-08-17 University Of Washington Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530499A (ja) * 2009-06-24 2012-12-06 メディカゴ インコーポレイテッド ヘマグルチニンを含むキメラインフルエンザウイルス様粒子
WO2014099931A1 (en) * 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US5182192A (en) 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
JP3037554B2 (ja) 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO1996011279A2 (en) 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
ATE426031T1 (de) 1995-09-14 2009-04-15 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
WO1997040177A1 (en) 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
WO1997040161A1 (en) 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
KR100894670B1 (ko) 1996-07-15 2009-04-22 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포융합 바이러스 백신의 생산
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
CN1232504A (zh) 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998053078A1 (en) 1997-05-23 1998-11-26 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
ATE361973T1 (de) 1997-07-11 2007-06-15 Univ Yale Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
JP4441595B2 (ja) 1998-06-12 2010-03-31 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー インターフェロン誘導性の遺伝子工学的に作製された弱毒ウイルス
PT1085904E (pt) 1998-06-12 2013-03-05 Sinai School Medicine Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6551820B1 (en) 1998-12-23 2003-04-22 Boyce Thompson Institute For Plant Research Expression of immunogenic hepatitis B surface antigens in transgenic plants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AU4134000A (en) 1999-04-29 2000-11-17 Syngenta Limited Herbicide resistant plants
DE122008000056I1 (de) 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren
DE60036952T2 (de) 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU2001250856A1 (en) 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
AU2001259211B2 (en) 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
HUE050222T2 (hu) 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP2006521095A (ja) 2003-01-29 2006-09-21 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 寛容誘導標的特異性抗体の生成
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4368594B2 (ja) 2003-02-24 2009-11-18 株式会社インシリコサイエンス タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
ZA200508930B (en) 2003-05-05 2007-03-28 Thompson Boyce Inst Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
PL1692265T3 (pl) 2003-11-04 2011-12-30 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
AU2005248377B2 (en) 2004-05-25 2011-03-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2006040764A2 (en) 2004-10-13 2006-04-20 Protalix Ltd. System and method for production of antibodies in plant cell culture
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
ZA200707258B (en) 2005-03-24 2008-06-25 Thromb X N V Novel anti-PLGF antibody
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
AU2006322907B2 (en) 2005-12-06 2012-08-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
KR20080106433A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
US20070262178A1 (en) 2006-05-12 2007-11-15 Ultradent Products, Inc. Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
EP2066345B1 (en) 2006-09-11 2015-02-25 Novartis AG Making influenza virus vaccines without using eggs
EP2174957B1 (en) 2007-06-15 2016-03-16 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
JP5187883B2 (ja) 2007-07-18 2013-04-24 独立行政法人科学技術振興機構 抗原ペプチドおよびその利用
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
WO2009025770A2 (en) 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
US9421254B2 (en) 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
FR2921387B1 (fr) 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
KR20100120157A (ko) 2007-11-27 2010-11-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
CA2708221C (en) 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US8592557B2 (en) 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
JP5756750B2 (ja) 2008-06-25 2015-07-29 インセルム（インスティチュート ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） フラジェリンに基づく新規の免疫アジュバント化合物及びその使用
EP2294202B1 (en) 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
WO2010036170A1 (en) 2008-09-23 2010-04-01 Nexam Chemical Ab Acetylenic polyamide
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
JP5463107B2 (ja) 2009-09-14 2014-04-09 独立行政法人国立国際医療研究センター 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
WO2011044152A1 (en) 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2545074A4 (en) 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
US20130034578A1 (en) 2010-04-09 2013-02-07 Petrus Josephus Marie Rottier Recombinant multimeric influenza proteins
CN105963694B (zh) 2010-04-30 2019-11-05 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法
AU2011282423B2 (en) 2010-07-22 2015-05-14 Schrader, Sabariah Cross-protective pathogen protection, methods and compositions thereof
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CN104066446B (zh) 2011-11-28 2017-10-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
CN103665155B (zh) 2012-09-14 2016-07-06 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1f2
KR101452865B1 (ko) 2012-09-17 2014-10-21 서울대학교산학협력단 신규한 ｉｐ－１０ 에피토프 및 이에 대한 항체
US10023629B2 (en) 2012-12-11 2018-07-17 Vib Vzw Anti-influenza antibody
RU2015132962A (ru) 2013-01-10 2017-02-14 Новартис Аг Иммуногенные композиции на основе вируса гриппа и их применение
ME03394B (me) 2013-02-22 2020-01-20 Medimmune Ltd Antidllз-antitelo-pbd konjugati i nihovа upotreba
JP6525469B2 (ja) 2013-03-13 2019-06-05 ノバルティス アーゲー インフルエンザｂ型ウイルス再集合
IL241552B2 (en) 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9879076B2 (en) 2013-03-15 2018-01-30 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
EP2968523A4 (en) 2013-03-15 2016-07-20 Univ Pennsylvania INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MANUFACTURED THEREOF
PL235555B1 (pl) 2014-06-24 2020-09-07 Inst Biotechnologii I Antybiotykow Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
PE20170291A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
EP3166962B1 (en) 2014-07-10 2019-08-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CN107847601A (zh) 2015-06-04 2018-03-27 南加利福尼亚大学 Lym‑1和lym‑2靶向的car细胞免疫疗法
WO2016205347A1 (en) 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US11236159B2 (en) 2015-08-03 2022-02-01 Novartis Ag Methods of treating FGF21-associated disorders
WO2017035479A1 (en) 2015-08-27 2017-03-02 Zimmer, Inc. Directional locking reverse shoulder prostheses and systems
US20200237898A1 (en) 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza
US10063211B2 (en) 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
US20190125859A1 (en) 2016-06-03 2019-05-02 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
WO2019032463A1 (en) 2017-08-07 2019-02-14 Icahn School Of Medicine At Mount Sinai IMMUNOGENIC COMPOSITIONS COMPRISING INFLUENZA VIRUS AND AS01 CHIMERIC POLYPEPTIDES OF HEMAGGLUTININ AND USES THEREOF
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530499A (ja) * 2009-06-24 2012-12-06 メディカゴ インコーポレイテッド ヘマグルチニンを含むキメラインフルエンザウイルス様粒子
WO2014099931A1 (en) * 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
US20180008696A1 (en) 2018-01-11
AU2016209032A1 (en) 2017-08-10
EP3247389A4 (en) 2019-10-30
EP3247389A1 (en) 2017-11-29
CA2974699A1 (en) 2016-07-28
US10736956B2 (en) 2020-08-11
WO2016118937A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
US10736956B2 (en) Influenza virus vaccination regimens
US10179806B2 (en) Influenza virus vaccines and uses thereof
US9849172B2 (en) Influenza virus vaccines and uses thereof
US20190125859A1 (en) Influenza virus vaccination regimens
JP6498439B2 (ja) インフルエンザウイルスワクチン及びその使用
EP2536425B1 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
JP2019141062A (ja) インフルエンザウイルスワクチン及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171019

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200616